NIFR Image-guided Surgery for Malignant Soft Tissue Tumor With Low-dose SWIG Technique
NCT ID: NCT06610071
Last Updated: 2024-09-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
PHASE1
592 participants
INTERVENTIONAL
2024-10-30
2030-12-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Investigation Into the Safety and Efficacy of ICG-Labeled Fluorescence Imaging Technology in Guiding the Resection of Bone and Soft Tissue Tumors
NCT06979115
Efficacy of ICG-based NIR Imaging in Intralesional Curettage of Giant Cell Tumors of Bone in Limbs: a Prospective, Single-center, Single-arm, Open Study
NCT06647901
Clinical Study of Radical Right Hemicolectomy Versus Radical Right Hemicolectomy Combined with Indocyanine Green Fluorescence Imaging Lymphatic Tracer Dissection for the Treatment of Right Colon Cancer
NCT06485609
A Prospective, Randomized, Open, Parallel-controlled, Superior-efficacy Clinical Study of Radical Sigmoidectomy for Sigmoid Cancer Versus Radical Sigmoidectomy Combined with Indocyanine Green Fluorescence Imaging Lymphatic Tracing Dissection in the Treatment of Sigmoid Cancer
NCT06396806
Application of ICG in Lymph Node Dissection During Radical Resection of Rectal Cancer With Preserved Autonomic Nerves Around LCA and IMA
NCT05517681
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Patients with DFSP in the first experimental group
The ICG was injected intravenously 24 hours before surgery at a dose of 0.25 mg/kg in the first experimental group.
ICG administration
The ICG was injected intravenously 24 hours before surgery at a dose of 0.25 mg/kg in the first experimental group.
Patients with DFSP in the second experimental group
The ICG was injected intravenously 24 hours before surgery at a dose of 25 mg/patient in the second experimental group.
ICG administration
The ICG was injected intravenously 24 hours before surgery at a dose of 25 mg/patient in the second experimental group.
Patients with DFSP in the control group
No interventions assigned to this group
Patients with sSCC in the first experimental group
The ICG was injected intravenously 24 hours before surgery at a dose of 0.25 mg/kg in the first experimental group.
ICG administration
The ICG was injected intravenously 24 hours before surgery at a dose of 0.25 mg/kg in the first experimental group
Patients with sSCC in the second experimental group
The ICG was injected intravenously 24 hours before surgery at a dose of 25 mg/patient in the second experimental group.
ICG administration
The ICG was injected intravenously 24 hours before surgery at a dose of 25 mg/patient in the second experimental group.
Patients with sSCC in the control group
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
ICG administration
The ICG was injected intravenously 24 hours before surgery at a dose of 0.25 mg/kg in the first experimental group.
ICG administration
The ICG was injected intravenously 24 hours before surgery at a dose of 25 mg/patient in the second experimental group.
ICG administration
The ICG was injected intravenously 24 hours before surgery at a dose of 0.25 mg/kg in the first experimental group
ICG administration
The ICG was injected intravenously 24 hours before surgery at a dose of 25 mg/patient in the second experimental group.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* hyperthyroidism
* pregnancy
* myasthenia gravis
* acute severe hypertension
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
1、 Department of Plastic and Reconstructive Surgery, Peking University Third Hospital
UNKNOWN
2、 Department of Plastic and Reconstructive Surgery, 1st Medical Center of Chinese PLA General Hospital
UNKNOWN
3、 Department of Plastic and Reconstructive Surgery, Peking University International Hospital
UNKNOWN
The Plastic Surgery Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Lei Cui
Principal Investigator
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Related Links
Access external resources that provide additional context or updates about the study.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CFH2024-2-4043
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.